Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | BACE1 | P56817 | 3/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467140 | 1.00 | BCHE (0.50) | BCHEACHEBACE1CACNA1GOPRL1 | |
| SCHEMBL7322347 | 1.00 | BCHE (0.50) | BCHEACHEBACE1CACNA1GOPRL1 | |
| SCHEMBL467142 | 1.00 | BCHE (0.50) | BCHEACHEBACE1CACNA1GOPRL1 | |
| SCHEMBL7323804 | 0.90 | ACHE (0.51) | BCHEACHEBACE1OPRL1CCR3 | |
| SCHEMBL7323800 | 0.90 | ACHE (0.51) | BCHEACHEBACE1OPRL1CCR3 | |
| SCHEMBL7321646 | 0.89 | GRIN2B (0.43) | — | |
| SCHEMBL534150 | 0.89 | DRD2 (0.41) | BCHEACHEBACE1CACNA1GOPRL1 | |
| SCHEMBL467075 | 0.89 | DRD2 (0.41) | BCHEACHEBACE1CACNA1GOPRL1 | |
| SCHEMBL467236 | 0.89 | DRD2 (0.41) | BCHEACHEBACE1CACNA1GOPRL1 | |
| SCHEMBL7321650 | 0.89 | GRIN2B (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5532243-A | SIGMA RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | claimed |
| EP-0626949-A1 | ANTIPSYCHOTIC NITROGEN-CONTAINING BICYCLIC COMPOUNDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-12-07 | — | — | EP | claimed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
| US-5532243-A | SIGMA RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0626949-A1 | ANTIPSYCHOTIC NITROGEN-CONTAINING BICYCLIC COMPOUNDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993016050-A1 | ANTIPSYCHOTIC NITROGEN-CONTAINING BICYCLIC COMPOUNDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |